fda tirzepatide shortage resolved 2025 says years-long is resolved, will give limited leeway to compounders FDA Resolves Tirzepatide Shortage: Impact

Prez said

Both oral tablets and injectable semaglutide activate the same GLP-1 receptors and produce comparable weight loss when dosed appropriately

In a significant milestone for type 2 diabetes care, Novo Nordisk has unveiled full results from its SOUL cardiovascular outcomes trial, confirming that oral semaglutide (14 mg) reduces the risk of major adverse cardiovascular events (MACE) by 14 per cent compared to placebo in adults with type 2 diabetes and existing cardiovascular and/or chronic kidney disease

Modifier use depends on the billing context

It helps neutralize free radicals, reduce inflammation, and promote the repair of damaged cells

Dont wait to feel better and take control of your health